Abstract 41P
Background
Most female carriers of germline BRCA1 mutation develop breast and/or ovarian cancer. However, the penetrance of BRCA1 pathogenic variants does not reach 100%, and the age at onset for BRCA1-associated breast cancer (BC) varies widely. This study aimed to evaluate whether the age-related likelihood of developing BC in BRCA1 mutation carriers is influenced by inherited variations in the host immune system.
Methods
Next-generation sequencing was utilized for genotyping of HLA class I and II genes (HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQB1, and HLA-DRB1/3/4/5) in patients with BRCA1-associated BC with early (<39 years, n = 215) and late (>57 years, n=108) age at onset. Age thresholds corresponding to the youngest and oldest quartiles of women were determined by analyzing the age distribution in 771 consecutive female BC patients carrying BRCA1 pathogenic variants.
Results
HLA-DQB1*06:03P prevalence was higher in the late-onset group due to the excess of allele carriers [25/108 (23.1%) vs. 22/215 (10.2%); adjusted OR 2.96 (95% CI 1.58 - 5.56), p < 0.001] and homozygous genotypes [3/108 (2.8%) vs. 0/215 (0%); OR 14.3 (95% CI 0.73 - 279.27), p = 0.08]. For all HLA-I loci, there was a trend toward an increase in the number of homozygous genotypes in the early-onset group. For the HLA-A locus this prevalence was significant [14.4% vs. 6.5%, p = 0.037; OR 2.4 (95% CI 1.03 - 5.72), p = 0.042]. The frequencies of HLA-DPB1, HLA-DQB1, and HLA-DRB3/4/5 homozygous genotypes did not differ between young-onset and late-onset BC patients. The maximum degree of homozygosity detected in this study was 6 out of 7 HLA class I/II loci; all six female carriers of these genotypes were diagnosed with BC before the age of 39 years [OR = 6.97 (95% CI 0.39 - 125.01), p = 0.187].
Conclusions
HLA-DQB1*06:03P is significantly overrepresented in late-onset versus young-onset BRCA1 heterozygous BC patients suggesting that this allele has a protective role. A reduced diversity of HLA class I alleles may contribute to the early manifestation of BC in BRCA1 mutation carriers.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation grant #22-15-00278.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Hypomethylated immune gene promoters as potential biomarkers in oral and oropharyngeal cancer
Presenter: Petra Anić
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Implementation of technical improvements in cfMeDIP-Seq library preparation
Presenter: Martina Dameri
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Clinical application of next-generation sequencing in metastatic colorectal cancer (mCRC): Experience from a comprehensive cancer centre
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
108P - Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study
Presenter: Rachel Dodds
Session: Cocktail & Poster Display session
Resources:
Abstract
109P - A multiomic, single-cell measurable residual disease (scMRD) assay for phasing DNA mutations and surface immunophenotypes
Presenter: Simone Formisano
Session: Cocktail & Poster Display session
Resources:
Abstract
110P - Multicellular three-dimensional tumor spheroid of nasopharyngeal carcinoma
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
111P - Development of digital PCR for accurate measurement of HER2 amplification in 184 gastric cancer patients
Presenter: So Young Kang
Session: Cocktail & Poster Display session
Resources:
Abstract
112P - A novel methylation-sensitive assay for early detection of hepatocellular carcinoma to improve surveillance
Presenter: Jeong Sil Ha
Session: Cocktail & Poster Display session
Resources:
Abstract
113P - Evaluation of effects of tissue preservation methods on the proteome abundance through deep proteomics of breast cancer tissue
Presenter: Shashwati parihari
Session: Cocktail & Poster Display session
Resources:
Abstract